Oculis Holding AG (FRA:CR5) Other Gross PPE : €1.01 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Other Gross PPE?

Oculis Holding AG's Other Gross PPE for the quarter that ended in Mar. 2024 was €1.01 Mil.

Oculis Holding AG's quarterly Other Gross PPE increased from Sep. 2023 (€1.16 Mil) to Dec. 2023 (€1.46 Mil) but then declined from Dec. 2023 (€1.46 Mil) to Mar. 2024 (€1.01 Mil).

Oculis Holding AG's annual Other Gross PPE increased from Dec. 2021 (€1.36 Mil) to Dec. 2022 (€1.38 Mil) and increased from Dec. 2022 (€1.38 Mil) to Dec. 2023 (€1.46 Mil).

Oculis Holding AG Other Gross PPE Historical Data

The historical data trend for Oculis Holding AG's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Other Gross PPE Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

1.38

1.36

1.38

1.46

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial							-	1.19	1.16	1.46	1.01

Oculis Holding AG Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Oculis Holding AG (FRA:CR5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

OCS:USA OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines